Study design: Beagle dogs received various doses of NanoDTPA^TM capsules to decorporate administered ²⁴¹Americium (²⁴¹Am). Efficacy of NanoDTPA^TM was compared to intravenously administered saline and Zn-DTPA.

Results: Both DTPA formulations increased urinary and fecal ²⁴¹Am excretion 10-fold compared to saline treatment and liver content of ²⁴¹Am was about eightfold decreased compared to control.

Conclusions: Oral NanoDTPA^TM capsules are comparable to intravenously administered Zn-DTPA in their efficacy to decorporate ²⁴¹Am in a dose dependent manner.